AbbVie (NYSE:ABBV) Stock Price Down 2.2% on Analyst Downgrade

AbbVie Inc. (NYSE:ABBV) dropped 2.2% during mid-day trading on Wednesday after Citigroup lowered their price target on the stock from $235.00 to $230.00. Citigroup currently has a neutral rating on the stock. AbbVie traded as low as $216.70 and last traded at $218.9880. 4,986,646 shares changed hands during trading, a decline of 31% from the average daily volume of 7,220,492 shares. The stock had previously closed at $223.93.

A number of other research analysts have also recently commented on the company. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Bank of America increased their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Raymond James Financial set a $256.00 price objective on AbbVie in a research report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $249.37.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Novartis announced multi?billion dollar licensing deals in oncology and Alzheimer’s, which could expand AbbVie’s long?term revenue runway and pipeline breadth. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Coverage of a bispecific trial “win” and AbbVie’s increased R&D focus could materially improve the bull case if confirmed — upside to sentiment and valuation depends on readouts and development milestones. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Analyst support: Berenberg raised its price target to $275 citing Skyrizi and Rinvoq momentum, signaling confidence in underlying specialty?drug growth. Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum
• Positive Sentiment: CNBC guest recommended staying long AbbVie, reflecting some bulls’ view that dividend, pipeline and specialty momentum justify ownership. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Positive Sentiment: Allergan Aesthetics posted new data (including TrenibotE and long?term onabotulinumtoxinA results) that support the aesthetics franchise—helpful for non?immunology revenue diversification. Allergan Aesthetics Unveils New Data Across Facial Injectables…
• Neutral Sentiment: Options flow has shown activity suggesting traders expect potential near?term volatility or a directional move, but this is ambiguous on direction. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Small institutional activity: Belpointe Asset Management modestly increased its stake — a relatively minor vote of confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Negative Sentiment: U.S. Medicare named several AbbVie drugs for the next round of price?negotiations — this raises medium?term downside risk to pricing and revenue for affected products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Competitive risk: Corcept reported robust Phase III ovarian?cancer data that could challenge treatments from Merck and AbbVie in that indication, implying potential market share pressure. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III…
• Negative Sentiment: Near?term earnings risk: Zacks notes AbbVie lacks the setup for a likely earnings beat next week; Citi trimmed its price target to $230 and put a neutral rating — both can weigh on share sentiment ahead of results. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth Benzinga

Hedge Funds Weigh In On AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Conning Inc. raised its position in AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after acquiring an additional 12,690 shares during the period. Diversified Trust Co increased its stake in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares in the last quarter. Dohj LLC lifted its position in shares of AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after acquiring an additional 1,335 shares in the last quarter. Permanent Capital Management LP purchased a new stake in shares of AbbVie during the third quarter worth approximately $720,000. Finally, Railway Pension Investments Ltd raised its stake in AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

The firm’s 50 day simple moving average is $225.14 and its 200-day simple moving average is $218.00. The company has a market cap of $387.04 billion, a price-to-earnings ratio of 165.90, a PEG ratio of 0.91 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.